Your browser doesn't support javascript.
loading
Clinical and Budget Impact of Treating Preoperative Anemia in Major Orthopedic Surgery-A Retrospective Observational Study.
Wan, Sike; Sparring, Vibeke; Cabrales, David A; Jansson, Karl Å; Wikman, Agneta.
Afiliación
  • Wan S; Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institute, Stockholm, Sweden.
  • Sparring V; Department of Learning, Informatics, Management and Ethics, Medical Management Centre, Karolinska Institute, Stockholm, Sweden; Health Care Services Stockholm County, Research and Development, Stockholm, Sweden.
  • Cabrales DA; Vifor Pharma Nordiska AB, Solna, Sweden.
  • Jansson KÅ; Department of Reconstructive Orthopedic Surgery, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
  • Wikman A; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
J Arthroplasty ; 35(11): 3084-3088, 2020 11.
Article en En | MEDLINE | ID: mdl-32654943
ABSTRACT

BACKGROUND:

Preoperative anemia (POA) in elective surgery is associated with worse outcome. In this retrospective study, in elective hip and knee arthroplasties, the prevalence of POA and its associations with outcome were analyzed, followed by a model estimating the budget impact of screening and treatment of POA.

METHODS:

All elective hip/knee arthroplasties performed during the period 2016-2018 were included. Patients with normal hemoglobin and patients with POA (hemoglobin < 13.0 g/dL in men and <12.0 g/dL in women) were compared. Outcome measures were allogeneic blood transfusion (ABT), length of stay (LOS), complications, mortality, and costs. The budget impact of screening for POA and treatment with intravenous iron when relevant was modeled based on the results of the costs related to POA.

RESULTS:

In 881 procedures, the prevalence of POA was 21.5%. POA independently predicted increased risks of ABT (odds ratio [OR]adj, 9.5 [confidence interval-CI, 6.4-13.9]), prolonged LOS (ORadj, 2.8 [CI, 1.8-4.2]), and was associated with increased complications (ORadj, 1.9 [CI, 0.7-4.9]) and mortality (ORadj, 3.2 [CI, 0.8-13.5]). POA resulted in increased costs per patient (P < .001). The budget impact model showed a cost reduction of 254 euros per patient based on the assumption that patients screened and treated for iron-deficient anemia would have the same outcome as non-POA.

CONCLUSION:

The prevalence of POA in elective orthopedic surgery in Sweden is at the same level as previously reported by others. Screening and treatment of POA would reduce costs based on less ABT and decreased LOS and may reduce complications in elective major orthopedic surgery.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Procedimientos Ortopédicos / Artroplastia de Reemplazo de Rodilla / Anemia Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Arthroplasty Asunto de la revista: ORTOPEDIA Año: 2020 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Procedimientos Ortopédicos / Artroplastia de Reemplazo de Rodilla / Anemia Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Arthroplasty Asunto de la revista: ORTOPEDIA Año: 2020 Tipo del documento: Article País de afiliación: Suecia